Clinical trial data on biliary tract cancer patients, suffering from a tumor that is frequently mutated in IDH1 locus [16], showed the inclusion of Trametinib as part of dual drug-combination treatment regime outperformed the clinical benefit of pan-FGFR kinase inhibitor BGJ398 plus IDH1Mut inhibitor Ivosidenib [17]. This evidence concerns the gene IDH1 and biliary tract neoplasm.